Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma.
Epigenetic alterations play an important role in carcinogenesis. Recent studies have suggested that global histone modifications are predictors of cancer recurrence in various tumor entities. Global histone acetylation levels (histone H3 lysine 9 acetylation [H3K9Ac], histone H3 lysine 18 acetylation [H3K18Ac], total histone H3 acetylation [H3Ac] and total histone H4 acetylation [H4Ac]) were determined in patients with renal cell carcinoma (RCC) using immunohistochemistry in a tissue micro array with 193 RCC and 10 oncocytoma specimens. The histone acetylation pattern was not different among the diverse histological subtypes of RCC or oncocytoma samples. The H3Ac levels were inversely correlated with pT-stage (P = 0.005), distant metastasis (P = 0.036), Fuhrman grading (P = 0.001) and RCC progression (P = 0.029, hazard ratio 0.87). H4Ac deacetylation was correlated with pT-stage (P = 0.011) and grading (P = 0.029). H3K18Ac levels were an independent predictor of cancer-progression following surgery for localized RCC in the univariate (P = 0.001, hazard ratio 0.78) and multivariate (P = 0.005, hazard ratio 0.82) analysis. In conclusion, our study supports the concept of global histone modification levels as a universal cancer prognosis marker, and provides evidence for the use of histone deacetylases inhibitors as future drugs in the therapy of RCC.
Mosashvilli
Davit
D
Department of Urology, University Hospital Bonn, Bonn, Germany.
Kahl
Philip
P
Mertens
Claudia
C
Holzapfel
Stefanie
S
Rogenhofer
Sebastian
S
Hauser
Stefan
S
Büttner
Reinhard
R
Von Ruecker
Alexander
A
Müller
Stefan C
SC
Ellinger
Jörg
J
D000107:Acetylation; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D044127:Epigenesis, Genetic; D005260:Female; D006657:Histones / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D046888:Tissue Array Analysis
D006657:Histones
Nat Genet. 2005 Apr;37(4):391-400
15765097
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4260-5
19255431
Biochem Cell Biol. 2009 Feb;87(1):139-50
19234530
Clin Cancer Res. 2010 Jan 1;16(1):141-53
20028765
Eur J Cancer. 2008 Aug;44(12):1701-9
18502115
Cancer Res. 2009 May 1;69(9):3802-9
19366799
Int J Cancer. 2010 Nov 15;127(10):2360-6
20162570
Prostate. 2010 Jan 1;70(1):61-9
19739128
J Cell Mol Med. 2009 Aug;13(8B):2115-2121
18752633
Cancer Res. 1995 Dec 15;55(24):6189-95
8521412
Science. 2003 Apr 18;300(5618):455
12702868
J Clin Oncol. 2005 Apr 20;23(12):2763-71
15837991
J Cell Mol Med. 2009 Aug;13(8B):2376-2385
18657224
Cancer Res. 1994 Jul 15;54(14):3682-5
8033084
Pathologe. 1987 May;8(3):138-40
3303008
Cell. 2007 Feb 23;128(4):693-705
17320507
Anal Quant Cytol Histol. 2007 Feb;29(1):17-31
17375871
J Natl Compr Canc Netw. 2009 Jun;7(6):659-65
19555587
J Clin Oncol. 2007 Oct 1;25(28):4358-64
17906200
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Am J Pathol. 2009 May;174(5):1619-28
19349354
BMC Cancer. 2008 Dec 19;8:381
19099586
J Urol. 2008 Sep;180(3):1131-6
18639283
Nature. 2005 Jun 30;435(7046):1262-6
15988529